Douglas J Swirsky - Net Worth and Insider Trading

Douglas J Swirsky Net Worth

The estimated net worth of Douglas J Swirsky is at least $197,142 dollars as of 2024-04-23. Douglas J Swirsky is the President & CEO of Genvec Inc and owns about 25,250 shares of Genvec Inc (GNVC) stock worth over $181,623. Douglas J Swirsky is the Director of Cellectar Biosciences Inc and owns about 2,500 shares of Cellectar Biosciences Inc (CLRB) stock worth over $7,975. Douglas J Swirsky is also the President and CEO of Rexahn Pharmaceuticals Inc and owns about 1,042 shares of Rexahn Pharmaceuticals Inc (REXN) stock worth over $7,544. Details can be seen in Douglas J Swirsky's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Douglas J Swirsky has not made any transactions after 2021-09-14 and currently still holds the listed stock(s).

Transaction Summary of Douglas J Swirsky

To

Douglas J Swirsky Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Douglas J Swirsky owns 8 companies in total, including NeuroBo Pharmaceuticals Inc () , Cellectar Biosciences Inc () , and Fibrocell Science Inc () among others .

Click here to see the complete history of Douglas J Swirsky’s form 4 insider trades.

Insider Ownership Summary of Douglas J Swirsky

Ticker Comapny Transaction Date Type of Owner
NeuroBo Pharmaceuticals Inc 2020-09-01 director
Cellectar Biosciences Inc 2021-09-14 director
Fibrocell Science Inc 2019-12-13 director
Rexahn Pharmaceuticals Inc 2019-01-29 director & President and CEO
Pernix Therapeutics Holdings Inc 2018-05-22 director
Genvec Inc 2017-06-16 director & President and CEO
Ocuphire Pharma Inc 2018-01-02 President and CFO
MaxCyte Inc 2023-03-27 Chief Financial Officer

Douglas J Swirsky Latest Holdings Summary

Douglas J Swirsky currently owns a total of 3 stocks. Among these stocks, Douglas J Swirsky owns 25,250 shares of Genvec Inc (GNVC) as of September 16, 2016, with a value of $181,623 and a weighting of 92.13%. Douglas J Swirsky owns 2,500 shares of Cellectar Biosciences Inc (CLRB) as of September 14, 2021, with a value of $7,975 and a weighting of 4.05%. Douglas J Swirsky also owns 1,042 shares of Rexahn Pharmaceuticals Inc (REXN) as of January 29, 2019, with a value of $7,544 and a weighting of 3.83%.

Latest Holdings of Douglas J Swirsky

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GNVC Genvec Inc 2016-09-16 25,250 7.19 181,623
CLRB Cellectar Biosciences Inc 2021-09-14 2,500 3.19 7,975
REXN Rexahn Pharmaceuticals Inc 2019-01-29 1,042 7.24 7,544

Holding Weightings of Douglas J Swirsky


Douglas J Swirsky Form 4 Trading Tracker

According to the SEC Form 4 filings, Douglas J Swirsky has made a total of 0 transactions in Genvec Inc (GNVC) over the past 5 years. The most-recent trade in Genvec Inc is the acquisition of 1,000 shares on September 16, 2016, which cost Douglas J Swirsky around $5,000.

According to the SEC Form 4 filings, Douglas J Swirsky has made a total of 1 transactions in Cellectar Biosciences Inc (CLRB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Cellectar Biosciences Inc is the acquisition of 2,500 shares on September 14, 2021, which cost Douglas J Swirsky around $26,000.

According to the SEC Form 4 filings, Douglas J Swirsky has made a total of 0 transactions in Rexahn Pharmaceuticals Inc (REXN) over the past 5 years. The most-recent trade in Rexahn Pharmaceuticals Inc is the acquisition of 1,042 shares on January 29, 2019, which cost Douglas J Swirsky around $31,500.

Insider Trading History of Douglas J Swirsky

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Douglas J Swirsky Trading Performance

GuruFocus tracks the stock performance after each of Douglas J Swirsky's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Douglas J Swirsky is -18.64%. GuruFocus also compares Douglas J Swirsky's trading performance to market benchmark return within the same time period. The performance of stocks bought by Douglas J Swirsky within 3 months outperforms 3 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Douglas J Swirsky's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Douglas J Swirsky

Average Return

-36.93%

Average return per transaction

Outperforming Transactions

22%

2 out of 9 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -9.04 -18.64 -14.77 -36.93 -46.14 -20.74
Relative Return to S&P 500(%) -10.73 -21.01 -19.9 -36.37 -45.76 -23.56

Douglas J Swirsky Ownership Network

Ownership Network List of Douglas J Swirsky

No Data

Ownership Network Relation of Douglas J Swirsky


Douglas J Swirsky Owned Company Details

What does NeuroBo Pharmaceuticals Inc do?

Who are the key executives at NeuroBo Pharmaceuticals Inc?

Douglas J Swirsky is the director of NeuroBo Pharmaceuticals Inc. Other key executives at NeuroBo Pharmaceuticals Inc include Acting Chief Financial Officer Marshall H Woodworth , Interim CEO and President Joseph Hooker , and 10 percent owner Goldman Sachs Group Inc .

NeuroBo Pharmaceuticals Inc () Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeuroBo Pharmaceuticals Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeuroBo Pharmaceuticals Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeuroBo Pharmaceuticals Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

NeuroBo Pharmaceuticals Inc Insider Transactions

No Available Data

Douglas J Swirsky Mailing Address

Above is the net worth, insider trading, and ownership report for Douglas J Swirsky. You might contact Douglas J Swirsky via mailing address: C/o Rexahn Pharmaceuticals, Inc., 15245 Shady Grove Road Suite 455, Rockville Md 20850.

Discussions on Douglas J Swirsky

No discussions yet.